A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy
(2020) In Allergy, Asthma and Clinical Immunology 16(1).- Abstract
Background: Allergen specific IgG4 levels have been monitored as a surrogate marker for the tolerance inducing effect of subcutaneous immunotherapy (SCIT) in many studies. Its accuracy at group level has been well established, but IgG4 has not yet found its place in the daily care of immunotherapy patients. Methods: Intralymphatic immunotherapy (ILIT) is a novel route for allergy vaccination against pollen allergy, where an ultrasound-guided injection of 1000 SQ-U Alutard is given directly into a groin lymph node. The suggested standard dosing so far has been one injection with 4 weeks in-between. In total 3000 SQ-U with the treatment completed in 2 months. IgG4 was measured with Immulite technique and rhinoconjunctivitis symptoms were... (More)
Background: Allergen specific IgG4 levels have been monitored as a surrogate marker for the tolerance inducing effect of subcutaneous immunotherapy (SCIT) in many studies. Its accuracy at group level has been well established, but IgG4 has not yet found its place in the daily care of immunotherapy patients. Methods: Intralymphatic immunotherapy (ILIT) is a novel route for allergy vaccination against pollen allergy, where an ultrasound-guided injection of 1000 SQ-U Alutard is given directly into a groin lymph node. The suggested standard dosing so far has been one injection with 4 weeks in-between. In total 3000 SQ-U with the treatment completed in 2 months. IgG4 was measured with Immulite technique and rhinoconjunctivitis symptoms were estimated with daily online questionnaires. Mann-Whitney U-test and Wilcoxon Signed Rank test were applied for comparisons between groups and within groups, respectively. Results: The present study demonstrates that a single, preseason ILIT booster of 1000 SQ-U Alutard 5-grasses®, re-increases the allergen specific timothy-IgG4 levels, in patients already treated with ILIT before the previous pollen season. It also shows the feasibility of the ILIT-route for allergy vaccination of rhinitis patients, with or without concomitant asthma, with low degree of side effects and reconfirms high and sustained patient satisfaction. Conclusions: It is tempting to suggest that the allergen specific IgG4 levels can be used to build an intuitive algorithm for future clinical guidance of ILIT patients.
(Less)
- author
- Weinfeld, Dan ; Westin, Ulla LU ; Hellkvist, Laila ; Mellqvist, Ulf Henrik ; Jacobsson, Ingvar and Cardell, Lars Olaf LU
- organization
- publishing date
- 2020-04-28
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Asthma, Grass pollen allergy rhinoconjunctivitis, IgG4, Intralymphatic immunotherapy, Randomized booster
- in
- Allergy, Asthma and Clinical Immunology
- volume
- 16
- issue
- 1
- article number
- 31
- publisher
- BioMed Central (BMC)
- external identifiers
-
- scopus:85085484527
- pmid:32368217
- ISSN
- 1710-1484
- DOI
- 10.1186/s13223-020-00427-z
- language
- English
- LU publication?
- yes
- id
- 3e9208a8-2416-41b9-bf83-5f77d4d64d72
- date added to LUP
- 2020-06-24 11:39:25
- date last changed
- 2024-05-29 15:10:27
@article{3e9208a8-2416-41b9-bf83-5f77d4d64d72,
abstract = {{<p>Background: Allergen specific IgG4 levels have been monitored as a surrogate marker for the tolerance inducing effect of subcutaneous immunotherapy (SCIT) in many studies. Its accuracy at group level has been well established, but IgG4 has not yet found its place in the daily care of immunotherapy patients. Methods: Intralymphatic immunotherapy (ILIT) is a novel route for allergy vaccination against pollen allergy, where an ultrasound-guided injection of 1000 SQ-U Alutard is given directly into a groin lymph node. The suggested standard dosing so far has been one injection with 4 weeks in-between. In total 3000 SQ-U with the treatment completed in 2 months. IgG4 was measured with Immulite technique and rhinoconjunctivitis symptoms were estimated with daily online questionnaires. Mann-Whitney U-test and Wilcoxon Signed Rank test were applied for comparisons between groups and within groups, respectively. Results: The present study demonstrates that a single, preseason ILIT booster of 1000 SQ-U Alutard 5-grasses<sup>®</sup>, re-increases the allergen specific timothy-IgG4 levels, in patients already treated with ILIT before the previous pollen season. It also shows the feasibility of the ILIT-route for allergy vaccination of rhinitis patients, with or without concomitant asthma, with low degree of side effects and reconfirms high and sustained patient satisfaction. Conclusions: It is tempting to suggest that the allergen specific IgG4 levels can be used to build an intuitive algorithm for future clinical guidance of ILIT patients. </p>}},
author = {{Weinfeld, Dan and Westin, Ulla and Hellkvist, Laila and Mellqvist, Ulf Henrik and Jacobsson, Ingvar and Cardell, Lars Olaf}},
issn = {{1710-1484}},
keywords = {{Asthma; Grass pollen allergy rhinoconjunctivitis; IgG4; Intralymphatic immunotherapy; Randomized booster}},
language = {{eng}},
month = {{04}},
number = {{1}},
publisher = {{BioMed Central (BMC)}},
series = {{Allergy, Asthma and Clinical Immunology}},
title = {{A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy}},
url = {{http://dx.doi.org/10.1186/s13223-020-00427-z}},
doi = {{10.1186/s13223-020-00427-z}},
volume = {{16}},
year = {{2020}},
}